Logo image of LHDX

LUCIRA HEALTH INC (LHDX) Stock Price, Forecast & Analysis

USA - NASDAQ:LHDX - US54948U1051 - Common Stock

0.4523 USD
-0.11 (-19.23%)
Last: 3/3/2023, 8:01:46 PM
0.405 USD
-0.05 (-10.46%)
After Hours: 3/3/2023, 8:01:46 PM

LHDX Key Statistics, Chart & Performance

Key Statistics
Market Cap18.36M
Revenue(TTM)212.13M
Net Income(TTM)-143.28M
Shares40.60M
Float29.97M
52 Week High4.35
52 Week Low0.11
Yearly DividendN/A
Dividend YieldN/A
EPS(TTM)-3.19
PEN/A
Fwd PEN/A
Earnings (Next)05-10 2023-05-10
IPO2021-02-05
Sector
GICS SectorHealth Care
GICS IndustryHealth Care Equipment & Supplies
GICS IndustryGroupHealth Care Equipment & Services
GICS SubIndustryHealth Care Equipment


LHDX short term performance overview.The bars show the price performance of LHDX in the last week, last 2 weeks, last month, last 3 and 6 months. 1 week 2 week 1 month 3 months 6 months 0 50 -50 100 150 200

LHDX long term performance overview.The bars show the price performance of LHDX in the last 1, 2 and 3 years. 1 year 2 years 3 years -20 -40 -60 -80

The current stock price of LHDX is 0.4523 USD. In the past month the price increased by 17.18%. In the past year, price decreased by -89.13%.

LUCIRA HEALTH INC / LHDX Daily stock chart

LHDX Latest News, Press Relases and Analysis

LHDX Competitors/Peers

The largest stocks on the US markets in the "Health Care Equipment" sub-industry
Full List
Symbol
Company Name
TA
FA
PE
Market Cap
ABT ABBOTT LABORATORIES 26.07 226.42B
ISRG INTUITIVE SURGICAL INC 64.69 199.66B
BSX BOSTON SCIENTIFIC CORP 35.16 153.71B
SYK STRYKER CORP 27.79 139.95B
IDXX IDEXX LABORATORIES INC 55.07 55.55B
BDX BECTON DICKINSON AND CO 13.42 55.47B
EW EDWARDS LIFESCIENCES CORP 33.56 50.63B
RMD RESMED INC 24.85 35.90B
GEHC GE HEALTHCARE TECHNOLOGY 16.02 33.58B
DXCM DEXCOM INC 31.8 23.20B
PODD INSULET CORP 73.53 23.65B
ZBH ZIMMER BIOMET HOLDINGS INC 11.09 17.78B

About LHDX

Company Profile

LHDX logo image Lucira Health, Inc. provides DNA testing services for medical, forensics, chemical, industrial, and agricultural applications. The company is headquartered in Emeryville, California and currently employs 221 full-time employees. The company went IPO on 2021-02-05. The firm is focused on providing disposable, single use test kit platform to replace central lab testing for diagnosing infectious diseases which leads to treatment and disease control outcomes. The firm has developed a testing platform that produces high-complexity-laboratory-accurate molecular testing in a single-use and user-friendly test kit that is powered by two AA batteries and fits in the palm of a hand. The company is also engaged in the commercialization of commercializing its PCR-quality COVID-19 test kits. Through its polymerase chain reaction (PCR)-quality technology, the Company offers single-use testing for infectious diseases. Its test kits are coupled with its digital platform, LUCI PASS, which is designed to securely deliver a clinically relevant test result to users at home, healthcare providers, and to required public health authorities. The firm has its operations in United States and Canada, among others.

Company Info

LUCIRA HEALTH INC

1315 63Rd Street

Emeryville CALIFORNIA 94608 US

CEO: Erik T. Engelson

Employees: 221

LHDX Company Website

Phone: 18145741546.0

LUCIRA HEALTH INC / LHDX FAQ

Can you describe the business of LUCIRA HEALTH INC?

Lucira Health, Inc. provides DNA testing services for medical, forensics, chemical, industrial, and agricultural applications. The company is headquartered in Emeryville, California and currently employs 221 full-time employees. The company went IPO on 2021-02-05. The firm is focused on providing disposable, single use test kit platform to replace central lab testing for diagnosing infectious diseases which leads to treatment and disease control outcomes. The firm has developed a testing platform that produces high-complexity-laboratory-accurate molecular testing in a single-use and user-friendly test kit that is powered by two AA batteries and fits in the palm of a hand. The company is also engaged in the commercialization of commercializing its PCR-quality COVID-19 test kits. Through its polymerase chain reaction (PCR)-quality technology, the Company offers single-use testing for infectious diseases. Its test kits are coupled with its digital platform, LUCI PASS, which is designed to securely deliver a clinically relevant test result to users at home, healthcare providers, and to required public health authorities. The firm has its operations in United States and Canada, among others.


What is the stock price of LUCIRA HEALTH INC today?

The current stock price of LHDX is 0.4523 USD. The price decreased by -19.23% in the last trading session.


Does LUCIRA HEALTH INC pay dividends?

LHDX does not pay a dividend.


What is the ChartMill technical and fundamental rating of LHDX stock?

LHDX has a ChartMill Technical rating of 5 out of 10 and a ChartMill Fundamental rating of 2 out of 10.


What is the market capitalization of LHDX stock?

LUCIRA HEALTH INC (LHDX) has a market capitalization of 18.36M USD. This makes LHDX a Nano Cap stock.


What is the next earnings date for LHDX stock?

LUCIRA HEALTH INC (LHDX) will report earnings on 2023-05-10.


Who owns LUCIRA HEALTH INC?

You can find the ownership structure of LUCIRA HEALTH INC (LHDX) on the Ownership tab.


LHDX Technical Analysis

ChartMill assigns a technical rating of 5 / 10 to LHDX. When comparing the yearly performance of all stocks, LHDX is a bad performer in the overall market: 87.4% of all stocks are doing better.


Chartmill TA Rating
Chartmill Setup Rating

LHDX Fundamental Analysis

ChartMill assigns a fundamental rating of 2 / 10 to LHDX. LHDX may be in some trouble as it scores bad on both profitability and health.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend

LHDX Financial Highlights

Over the last trailing twelve months LHDX reported a non-GAAP Earnings per Share(EPS) of -3.19. The EPS decreased by -84.6% compared to the year before.


Industry RankSector Rank
PM (TTM) N/A
ROA N/A
ROE N/A
Debt/Equity 0.48
Chartmill High Growth Momentum
EPS Q2Q%-570.21%
Sales Q2Q%129.63%
EPS 1Y (TTM)-84.6%
Revenue 1Y (TTM)564.27%

LHDX Forecast & Estimates

6 analysts have analysed LHDX and the average price target is 0.77 USD. This implies a price increase of 69.14% is expected in the next year compared to the current price of 0.4523.

For the next year, analysts expect an EPS growth of 83% and a revenue growth 201.55% for LHDX


Analysts
Analysts43.33
Price Target0.77 (70.24%)
EPS Next Y83%
Revenue Next Year201.55%

LHDX Ownership

Ownership
Inst OwnersN/A
Ins Owners13.86%
Short Float %N/A
Short RatioN/A